Showing results (131-140 of 494) with videos related to
Sort By:
Pageof 50
BMJ (Clinical Research Ed.)|October 25, 2019
Public sector financial support for late stage discovery of new drugs in the United States: cohort studyRahul K Nayak, Jerry Avorn, Aaron S KesselheimMayo Clinic Proceedings|October 5, 2020
Clinical Development Times for Biosimilars in the United StatesChangWon C Lee, Aaron S Kesselheim, Ameet SarpatwariJournal of Health Politics, Policy and Law|July 25, 2022
The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible ReformsAmeet Sarpatwari, Aaron S Kesselheim, Robert Cook-DeeganCommunications Medicine|September 15, 2021
Mitigating bias in machine learning for medicineKerstin N Vokinger, Stefan Feuerriegel, Aaron S KesselheimEclinicalmedicine|May 9, 2020
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugsBishal Gyawali, Spencer P Hey, Aaron S KesselheimClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 29, 2021
Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?Reed F Beall, Aaron S Kesselheim, Aidan HollisJAMA|June 7, 2011
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancerAaron S Kesselheim, Jessica A Myers, Jerry AvornJAMA Internal Medicine|October 13, 2015
Physicians and Insider TradingAaron S Kesselheim, Michael S Sinha, Steven JoffeClinical Pharmacology and Therapeutics|May 31, 2026
Orphan Designation for Drugs Approved in the United States and European Union: A Comparative AnalysisEnrico Costa, Joseph S Ross, Aaron S KesselheimPlos Medicine|March 6, 2023
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measuresBeatrice L Brown, Aaron S Kesselheim, Ameet SarpatwariPageof 50